Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002018766-26-000002
Filing Date
2026-01-09
Accepted
2026-01-09 20:36:10
Documents
3
Period of Report
2026-01-08

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1768008966.html 4  
1 FORM 4 wk-form4_1768008966.xml 4 4022
2 EX-24.1 znt-powerofattorneyxvinc.htm EX-24.1 648
3 znt-powerofattorneyxvinc001.jpg GRAPHIC 224258
  Complete submission text file 0002018766-26-000002.txt   315325
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Vultaggio Vincent (Reporting) CIK: 0002018766 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 26524460